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Cardiac signaling genes exhibit 
unexpected sequence diversity in sporadic 
cardiomyopathy, revealing HSPB7 
polymorphisms associated with disease
Scot J. Matkovich,1 Derek J. Van Booven,1 Anna Hindes,1 Min Young Kang,1  
Todd E. Druley,2,3 Francesco L.M. Vallania,3 Robi D. Mitra,3 Muredach P. Reilly,4  
Thomas P. Cappola,4 and Gerald W. Dorn II1
1Center for Pharmacogenomics, Department of Medicine, 2Division of Pediatric Hematology and Oncology, Department of Pediatrics, and  
3Center for Genome Sciences, Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA.  
4Penn Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Sporadic	heart	failure	is	thought	to	have	a	genetic	component,	but	the	contributing	genetic	events	are	poorly	
defined.	Here,	we	used	ultra-high-throughput	resequencing	of	pooled	DNAs	to	identify	SNPs	in	4	biologically	
relevant	cardiac	signaling	genes,	and	then	examined	the	association	between	allelic	variants	and	incidence	of	
sporadic	heart	failure	in	2	large	Caucasian	populations.	Resequencing	of	DNA	pools,	each	containing	DNA	
from	approximately	100	individuals,	was	rapid,	accurate,	and	highly	sensitive	for	identifying	common	and	
rare	SNPs;	it	also	had	striking	advantages	in	time	and	cost	efficiencies	over	individual	resequencing	using	
conventional	Sanger	methods.	In	2,606	individuals	examined,	we	identified	a	total	of	129	separate	SNPs	in	
the	4	cardiac	signaling	genes,	including	23	nonsynonymous	SNPs	that	we	believe	to	be	novel.	Comparison	of	
allele	frequencies	between	625	Caucasian	nonaffected	controls	and	1,117	Caucasian	individuals	with	systolic	
heart	failure	revealed	12	SNPs	in	the	cardiovascular	heat	shock	protein	gene	HSPB7	with	greater	proportional	
representation	in	the	systolic	heart	failure	group;	all	12	SNPs	were	confirmed	in	an	independent	replication	
study.	These	SNPs	were	found	to	be	in	tight	linkage	disequilibrium,	likely	reflecting	a	single	genetic	event,	but	
none	altered	amino	acid	sequence.	These	results	establish	the	power	and	applicability	of	pooled	resequencing	
for	comparative	SNP	association	analysis	of	target	subgenomes	in	large	populations	and	identify	an	associa-
tion	between	multiple	HSPB7	polymorphisms	and	heart	failure.
Introduction
Application of genetic testing and linkage analysis to rare inherited 
disorders has uncovered thousands of causative genetic mutations 
and revealed much about disease pathophysiology and process (1). 
Identifying genetic causes for common diseases such as hyperten-
sion, diabetes, and heart failure has proven more challenging, likely 
because these complex syndromes develop as a consequence of 
interactions among multiple genetic and nongenetic factors. Fur-
thermore, familial transmission of these disorders is inconsistent, 
disease penetrance tends to be incomplete, and the phenotypes can 
be highly variable. For these reasons, attempts to delineate genetic 
influences in common diseases have eschewed studies of familial 
transmission in favor of large-scale genetic association analyses that 
compare the frequencies of gene variants between affected cases 
and nonaffected controls. Genetic mapping of SNPs located at set 
intervals across the entire genome of thousands of individuals using 
microarray-based platforms has reproducibly implicated specific 
genetic loci in cancer, diabetes, hypertension, coronary atheroscle-
rosis, and other diseases (2–6). However, assignment of the basis for 
gene effects and advancing our understanding into disease mecha-
nisms requires resequencing across linked loci to identify causal 
mutations. In many cases, this has not yet been achieved.
Polygenic models for complex diseases propose that a significant 
component of genetic susceptibility is found in combinatorial 
interactions of multiple rare deleterious mutations (7, 8). Accord-
ingly, the ultimate goal for studies correlating genotype and phe-
notype should be to identify all gene variants at multiple loci, both 
common and rare. This requires deep resequencing in very large 
and well-characterized patient populations (9). A first step is the 
NIH 1,000 Genomes Project, in which entire individual genomes 
are being independently resequenced at an estimated cost of at 
least $30 million and will be collectively analyzed to generate a map 
of all human allelic variants with a frequency greater than 1% (10). 
More time- and cost-efficient gene mapping and identification of 
genetic modifiers for common diseases could be accomplished 
by targeted genetic analysis of pooled case and control samples. 
However, pooled genotyping is not compatible with conventional 
Sanger or microarray-based sequencing techniques.
We recently developed a targeted, pooled sample sequencing 
strategy (11) that, coupled with novel computational algorithms 
and second-generation DNA sequencing platforms (12, 13), accu-
rately identified the position and frequency of common and rare 
SNPs in a random pediatric population of 1,111 individuals. Here, 
we have explored the applicability of these techniques to catalog 
nucleotide sequence diversity in a large adult population and to 
perform a SNP association study of systolic heart failure in 4 bio-
logically relevant cardiac signaling genes: α1-adrenergic receptor 
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(ADRA1A), β2-adrenergic receptor (ADRB2; refs. 14, 15), phos-
pholamban (PLN; refs. 16, 17), and the cardiovascular heat shock 
protein (HSP) gene HSP27 member 7 (HSPB7; ref. 18). SNP call-
ing using pooled sample resequencing was reproducible and, in 
comparison with individual Sanger sequencing of ADRA1A exon 2, 
both accurate and sensitive. We identified 55 common SNPs (com-
mon defined in the present study as greater than 1% overall allele 
frequency within a population of similar geographic ancestry) and 
74 rare SNPs (rare defined as less than 1% overall allele frequency). 
Of these, 7 common SNPs were nonsynonymous (i.e., the genetic 
alteration changed an encoded amino acid), all of which are previ-
ously described in the SNP database (dbSNP; ref. 19), and 29 rare 
SNPs were nonsynonymous, 23 of which were novel. Comparison 
of common SNP allele frequencies in a Caucasian population 
(where Caucasian is defined as mixed European descent) between 
systolic heart failure cases and nonaffected controls revealed a 
haplotype block of 12 synonymous or intronic 
HSPB7 SNPs in tight linkage disequilibrium 
that were significantly and reproducibly associ-
ated with systolic heart failure.
Results
Pooled DNA resequencing to detect and quantify SNPs 
in a large population. To catalog nucleotide varia-
tions within the 4 target gene exons, we ampli-
fied and resequenced 5 loci covering 9.4 kb of 
nonamplified genomic DNA archived from 2,606 
individuals — 1,742 Caucasians and 864 African 
Americans — who had participated in a longi-
tudinal study of systolic heart failure (20). The 
coding regions for ADRA1A, ARDB2, HSPB7, and 
PLN were comprehensively examined (Figure 1). 
In initial studies determining the capabilities 
and limits of our pooled resequencing approach, 
genomic DNA from the study population was 
combined into 12 DNA pools of approximately 
250 individuals per pool.
To determine the consistency of SNP calling 
by Illumina Genome Analyzer resequencing and 
our analysis pipeline, sequencing libraries were 
prepared from the 12 DNA pools and separately 
amplified and sequenced on 2 different machines 
at 2 different times. The data were analyzed in 
an identical manner, and allele frequencies were 
compared. The reported allele frequencies for 
confirmed SNPs were highly concordant between 
the 2 sequencing runs across the entire range 
(r2 = 0.991; P = 9 × 10–122; Figure 2A).
Next, we evaluated the reproducibility of SNP identification and 
quantification as a function of preparing different sequencing 
libraries from the same DNA pools, or of starting with different 
DNA pools prepared from the same group of individual DNAs. 
This comparison examined variability introduced by differences 
in DNA handling and amplification. The correlation of reported 
allele frequencies in different sequencing libraries prepared from 
identical pools was as good as that from libraries prepared from 
different pools containing the same collection of individual DNAs 
(r2 = 0.993 and 0.994, respectively; P < 1 × 10–70; Figure 2, B and C).
Depth of sequence coverage using the pooled DNA sequenc-
ing approach is determined in part by the number of individual 
genomes added per single Illumina lane; for our experimental 
design, this corresponded with the number of individuals in 
each pool. For our initial studies using 12 pools of about 250 
Figure 1
Position of 129 signaling gene SNPs identified by 
pooled sequencing. Schematics show the exonic 
structure of the 4 target genes. Black boxes rep-
resents coding regions; white boxes represent 5′ 
and 3′ untranslated regions. Genomic PCR primer 
positions are shown with arrows. Detected SNPs 
are indicated by position and numbering from 
translation start site. Black lines indicate SNPs 
in dbSNP (19); red lines indicate novel SNPs. (A) 
Results for Caucasians (Cauc). (B) Results for 
African Americans (AA).
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individuals, sequence coverage for SNP calling (first 12 nucleo-
tides only) averaged 10-fold per diploid genome. Coverage depth 
for the noncoding region of PLN, which has low sequence com-
plexity due to the presence of multiple dinucleotide repeats, was 
not as great (3-fold per diploid genome). To assess the impact of 
increasing sequence coverage on SNP calling, we resequenced the 
5 genetic loci in the study cohort divided into 29 pools containing 
approximately 100 individual DNAs (range, 75 to 125). With this 
DNA pooling design and intercurrent improvements in Illumina 
sequencing chemistry (21), and by sequencing the library from 
each pool in a separate lane, we found average sequence coverage 
depth increased to 43-fold (11-fold for PLN noncoding).
SNP identification was compared between the 250 individuals 
per pool (12-pool) and 100 individuals per pool (29-pool) stud-
ies. A total of 129 separate SNPs (55 common, 74 rare) were iden-
tified and validated in the 29-pool study. Correlation of allele 
frequencies for SNPs reported in both the 12- and 29-pool stud-
ies was excellent (r2 = 0.990, P = 4.2 × 10–115; Figure 2D). Of 81 
SNPs reported in the 12-pool study, 77 (95%) were detected in the 
29-pool study, but 49 validated SNPs reported in the 29-pool 
design had not fulfilled validation criteria in the 12-pool studies. 
Of these newly validated SNPs, 47 were rare (Caucasians, median 
allele frequency 0.0008, range 0.0003 to 0.005; African Americans, 
median allele frequency 0.014, range 0.0006 to 0.019), and 2 were 
private (Caucasians, allele frequency 0.0003; African Americans, 
allele frequency 0.0006). Thus, DNA pooling into smaller groups of 
about 100 individuals improved detection of rare SNPs by increas-
ing sequence coverage depth and by affording greater opportunity 
for SNP calling in multiple different pools.
We examined the sensitivity and specificity of Illumina pooled 
resequencing in comparison to the previous gold standard, conven-
tional Sanger resequencing of individual DNAs. Pooled sequencing 
showed that the 5′ end of the ADRA1A exon 2 contains 15 SNPs 
(7 reported in HapMap and 8 novel), with allele frequencies rang-
ing from approximately 50% to a singleton (Figure 1 and Table 1). 
Therefore, we individually Sanger resequenced this amplicon for 
each subject DNA. Of the 2,606 DNAs amplified and submitted, 
confident Sanger sequence was returned on 2,506 (1,666 Cauca-
sians and 840 African Americans; 96% overall sequence success 
rate). SNP allele frequencies generated by pooled and individual 
resequencing are compared in Table 1, reported separately for 
Caucasians and African Americans. Pooled Illumina resequencing 
and individual Sanger resequencing identified the same 15 SNPs. 
Pooled sequencing detected 5 confirmed singletons in the Cauca-
sian subgroup (+1,074, +1,172, +1,203, +1,311, and +1,443) and 
1 SNP that occurred only twice in this group (+927). However, 
within the Caucasian and African American subgroups, pooled 
resequencing failed to detect a rare SNP in the Caucasian subgroup 
that was detected on Sanger sequence (+996); this also occurred 
once in the African American cohort (+1,124). In both instances, the 
SNP had been bioinformatically filtered from the pooled sequenc-
ing results because it was novel and not detected in more than 1 
DNA pool, or in both the 29-pool and 12-pool studies. For the 
3 common SNPs (+1,039, +1,395, and +1,617), the allele frequencies 
generated by pooled Illumina sequencing were comparable to those 
from individual Sanger sequencing. These results show that allele 
frequencies for common SNPs obtained by Illumina resequencing 
of pools of about 100 individual DNAs were sufficiently accurate 
for between-group comparisons. These data also demonstrate that 
pooled resequencing and our analysis pipeline can be highly sensi-
tive for the detection of rare and private SNPs in large populations, 
although stochastic variation and our filtering criteria made for 
less than absolute sensitivity in all pools. Based on this finding, 
we determined that quantitative comparisons of individual SNP 
allele frequencies between population groups are best performed 
on common SNPs and that a more qualitative approach should be 
used to evaluate rare and private SNPs.
Allele frequencies in population subgroups with different geographic ances-
tries. Resequencing target genes across a large population should be 
useful to identify alleles that are differentially represented between 
Figure 2
Allele frequency comparisons with Illumina resequenc-
ing of pooled DNA. (A) Comparison of SNP allele fre-
quencies from 2 independent runs of identical sequenc-
ing libraries made from 12 pools of 2,606 individual 
DNAs. (B) Comparison of SNP allele frequencies from 
2 independent runs of separate libraries made from 
the same DNA pools. (C) Comparison of SNP allele 
frequencies from 2 independent runs of libraries made 
from replicate DNA pools. (D) Comparison of SNP allele 
frequencies obtained from resequencing the same 
2,606 individual DNAs, grouped into pools of approxi-
mately 250 individual DNAs (12 pools) versus approxi-
mately 100 individual DNAs (29 pools). Formulae for 
regression line and Pearson correlation coefficient are 
indicated for each analysis.
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population subgroups. We recently showed that differences in 
SNP frequency between 2 groups with different genetic ancestries 
can confound the results of systolic heart failure outcome stud-
ies when genotype is not an a priori consideration in experimental 
design (20). Racial differences in SNP frequencies are reported in 
the HapMap, but the number of individuals from some ancestral 
subgroups can be small. Therefore, we used pooled DNA resequenc-
ing to examine SNP diversity within our 4 target genes in 625 Cau-
casian and 236 African American subjects who did not have heart 
disease at the time of study entry. A total of 110 SNPs were detected 
in the normal subjects, 48 of which were novel (Table 2 and Supple-
mental Table 1; supplemental material available online with this 
article; doi:10.1172/JCI39085DS1). We found 27 SNPs to be non-
synonymous (encoded a change in amino acid), 16 of which were 
novel (Table 2 and Supplemental Table 1). Even though our sample 
number for African Americans was only about one-third that for 
Caucasians, African Americans had 84 SNPs compared with 69 in 
Caucasians. Moreover, 41 SNPs were exclusive to African Americans 
(including 7 in the 3′ untranslated region of ADRB2 and 15 in the 
second intron and third exon of HSPB7), and 26 SNPs were exclu-
sive to Caucasians (including 12 in the coding region of ADRA1A 
and 7 in the coding region of ADRB2; Supplemental Table 1 and 
Figure 3A). Of the 42 SNPs present in both population subgroups, 
the allele frequencies differed significantly (P < 0.0005; α = 0.05) 
between African Americans and Caucasians in 27, and in 24 of these 
instances, the allele frequency was significantly greater in African 
Americans (Table 2 and Figure 3A). These results reveal substantial 
nucleotide sequence diversity in the 4 target genes as a function 
of geographic ancestry and support SNP association study designs 
that analyze Caucasians and African Americans separately.
Common signaling gene polymorphisms associated with systolic heart fail-
ure. Another instance in which pooled resequencing should have 
advantages over individual resequencing is to identify alleles (espe-
cially those that are not represented 
on marker SNP arrays) that are 
differentially represented between 
diseased cases and nonaffected con-
trols. Accordingly, we used pooled 
DNA resequencing for a case-con-
trol gene association study of systol-
ic heart failure among Caucasians. 
We compared allele frequencies for 
the 37 common SNPs identified in 
our pooled DNA resequencing of 
1,117 Caucasian heart failure cases 
(the 29-pool study) with 625 Cau-
casian controls from the University 
of Cincinnati, and confirmed asso-
ciated SNPs in a replication pooled 
sequencing analysis of 859 Cauca-
sian heart failure cases and 311 Cau-
casian controls from the University 
of Pennsylvania. Detailed clinical 
characteristics of the systolic heart 
failure study population, stratified 
by geographic ancestry, have been 
reported elsewhere (20). A summary 
of demographic and clinical features 
of the study subjects is shown in 
Table 3. The DNA pooling strategy 
for the study groups is shown in Supplemental Figure 1.
Our 4 target genes were selected because of their postulated rel-
evance to cardiac physiology and disease (22–24). Therefore, we were 
gratified to find genotype-phenotype associations (Table 4 and Sup-
plemental Table 2). Of the 37 common SNPs analyzed in the case-
control cohort, 12 SNPs spanning exons 1–3 of HSPB7, including in 
the intervening 2 introns, achieved the P < 0.0014 (α = 0.05) thresh-
old for significance in the primary cohort (Figure 3B and Table 4). 
These SNPs were in tight linkage disequilibrium (Figure 3B), and 
therefore likely indicate a common genetic event. The association of 
each of these HSPB7 SNPs was replicated in a subsequent study of 
independent heart failure cases and controls (P < 0.0211; α = 0.05; 
effective number of independent SNPs, 2.36; Table 4).
The heart failure study cohorts consisted of a mixture of isch-
emic and nonischemic (also known as idiopathic) cardiomyopa-
thies, but our DNA pooling strategy permitted us to separately 
examine the association of HSPB7 polymorphisms with each eti-
ology. In the primary cohort of 691 with ischemic cardiomyopa-
thy and 426 with nonischemic cardiomyopathy, multiple SNPs 
within the HSPB7 haplotype block were significant in both etio-
logical subgroups (Supplemental Table 3), which suggests that the 
association of this HSPB7 haplotype applies to both ischemic and 
nonischemic cardiomyopathies.
Although we were underpowered to perform a comprehensive 
SNP association analysis of African American systolic heart failure, 
we examined our limited cohort of 628 African American cases and 
236 African American controls to determine whether any of the 
HSPB7 SNP associations detected in the primary Caucasian cohort 
were present in this subgroup. African American systolic heart fail-
ure was similar to Caucasian heart failure in terms of age, height, 
weight, and degree of left ventricular dysfunction (ejection frac-
tion), but, consistent with previous observations (25, 26), hyperten-
sion and nonischemic cardiomyopathy were more prevalent (20). 
Table 1
ADRA1A exon 2 SNP allele frequencies from pooled Illumina versus individual Sanger sequencing
dbSNP	 Position	 Type	 Major	 Minor	 Codon	 Pooled	Illumina	 Individual	Sanger
	 	 	 allele	 allele	 	 Cauc	 AA	 Cauc	 AA
 +927 Coding S A G K309K 0.0004 – 0.0006 –
 +996 Coding S G A E332E – 0.0014 0.0009 0.0027
rs1048101 +1,039 Coding NS T C C347R 0.4373 0.7435 0.4856 0.7611
rs56318220 +1,074 Coding S C T Y358Y 0.0003 – 0.0004 –
rs61731555 +1,123 Coding NS G T V375L – 0.0017 – 0.0016
 +1,124 Coding NS T G V375G 0.0006 – 0.0015 0.0024
 +1,172 Coding NS C T T391M 0.0003 – 0.0004 –
 +1,173 Coding S G A T391T – 0.0023 – 0.0031
 +1,203 Coding S T G S401S 0.0004 0.0019 0.0004 0.0031
 +1,311 Coding S G T G437G 0.0003 – 0.0004 –
rs2229126 +1,395 Coding NS A T E465D 0.0308 0.0278 0.0232 0.0221
 +1,443 3′UTR C A  0.0003 0.0008 0.0004 –
rs61760513 +1,460 3′UTR C A  0.0003 0.0062 0.0009 0.0043
rs61760511 +1,563 3′UTR G T  0.0035 0.0013 0.0048 0.0035
rs73678233 +1,617 3′UTR C T  0.0012 0.0661 0.0015 0.0487
Illumina sequencing was performed on 19 pools of 1,742 Caucasians (Cauc) and 9 pools of 864 African 
Americans (AA). Sanger sequencing was successful for 1,666 Caucasians and 840 African Americans 
assayed individually. For SNPs in HapMap, the rs number from dbSNP (19) is shown. Position is from the 
translation initiation codon. S, synonymous; NS, nonsynonymous; UTR, untranslated region. Values in the 
codon column show the amino acid. Allele frequencies of ~0.0003 and ~0.0006 correspond to singletons in 
Caucasians and African Americans, respectively.
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There was no association among any of the HSPB7 SNPs with sys-
tolic heart failure in African Americans (Supplemental Table 4).
Impact of nonsynonymous signaling gene polymorphisms on systolic 
heart failure. Our case-control study of systolic heart failure in 
Caucasians examined only common 
SNPs. Although 3 of the 12 associ-
ated HSPB7 SNPs were in coding 
exons, they did not alter amino acid 
sequence (Figure 3B and Table 4). 
Nevertheless, it is estimated that 50% 
of rare nonsynonymous SNPs can 
be deleterious (27). For this reason, 
we investigated the impact on heart 
failure by rare and common non-
synonymous SNPs in the 4 target 
genes. First, we used computational 
algorithms SIFT and PolyPhen (28, 
29) to categorize the likelihood that 
the nonsynonymous SNPs could be 
harmful, based upon sequence con-
servation, protein structure, and 
annotated protein features. All cod-
ing SNPs in the target genes were 
classified as either synonymous 
(expected to be biologically neutral), 
nonsynonymous and presumed 
benign (both algorithms agreed), 
nonsynonymous and presumed 
pathological (both algorithms 
agreed), or nonsynonymous with 
uncertain consequences (algorithms 
differed) (Supplemental Tables 5 
and 6). Case-control comparisons 
of allele frequencies were performed 
for common SNPs (analyzed indi-
vidually; Supplemental Table 5) and 
rare SNPs (analyzed individually 
and collectively as functionally simi-
lar groups; Supplemental Table 6). 
For common SNPs, there were 7 
nonsynonymous SNPs, only one of 
which (ADRA1A I200S) was clas-
sified as presumed pathological. 
Allele frequencies for this SNP were 
approximately 0.02 in Caucasians 
and approximately 0.002 in Afri-
can Americans, with no differences 
between heart failure cases and con-
trols. For rare SNPs, there were 29 
nonsynonymous SNPs (of which 16 
were in ADRA1A): 13 were classified 
as presumed benign, 10 as presumed 
pathological, and 6 as uncertain 
(Supplemental Table 6). Again, there 
were no differences in allele frequen-
cies between heart failure cases and 
controls for these SNPs, either indi-
vidually or combined into function-
ally similar groups.
Discussion
Here, we used large-scale pooled sequencing of phenotypically 
similar individuals to identify and quantify common and rare 
SNPs in a target cardiac signaling subgenome and applied this 
Table 2
Comparative allele frequencies of target gene SNPs in Caucasians and African Americans
dbSNP	 Position	 Type	 Major	 Minor	 Codon	 Cauc	 AA	 P	
	 	 	 allele	 allele	 	 controls	 controls
ADRA1A
 +320 Coding NS T G V17G 0.0024 0.0079 0.0945
rs2229125 +599 Coding NS T G I200S 0.0216 0.0017 0.0022
rs382423 I1+53 Intronic G T  0.0162 0.0095 0.3555
rs14811 +1,039 Coding NS T C C347R 0.4317 0.7023 <0.0001A
rs2229126 +1,395 Coding NS A T E465D 0.0243 0.0226 1.0000
rs6176513 +1,460 3′UTR C A  0.0008 0.0110 0.0071
rs6176511 +1,563 3′UTR G T  0.0030 0.0021 1.0000
rs73678233 +1,617 3′UTR C T  0.0011 0.0591 <0.0001A
rs3739216 +1,818 3′UTR C G  0.0742 0.1800 <0.0001A
ADRB2
rs142711 –47 5′UTR C T  0.6161 0.8451 <0.0001A
rs18174 –20 5′UTR C T  0.6185 0.8415 <0.0001A
rs142713 +46 Coding NS G A G16R 0.3985 0.4781 0.0031
rs142714 +79 Coding NS G C E27Q 0.5716 0.8165 <0.0001A
rs142717 +252 Coding S G A L84L 0.2165 0.3965 <0.0001A
rs142718 +523 Coding S C A R175R 0.2004 0.3892 <0.0001A
rs142719 +1,053 Coding S G C G351G 0.2995 0.3851 0.0008A
rs14272 +1,239 Coding S G A L413L 0.3256 0.5402 <0.0001A
rs8192451 +1,620 3′UTR C T  0.0150 0.0064 0.2267
HSPB7
rs373864 –8 5′UTR G A  0.1061 0.0410 <0.0001A
rs945416 +57 Coding S C T S19S 0.5383 0.6737 <0.0001A
rs732286 +99 Coding S T C A33A 0.5171 0.6639 <0.0001A
rs3883891 I1+177 Intronic A G  0.3730 0.3590 0.5762
rs1739845 I1–113 Intronic G T  0.0501 0.0788 0.0369
rs3738643 I2+245 Intronic C G  0.1116 0.0404 <0.0001A
rs1739844 I2+247 Intronic A G  0.5109 0.6735 <0.0001A
rs1763597 I2+272 Intronic G A  0.5276 0.6988 <0.0001A
rs1739843 I2+315 Intronic A G  0.5432 0.7014 <0.0001A
rs12758813 I2+490 Intronic C T  0.4173 0.4350 0.5476
rs1739842 I2–594 Intronic A C  0.5235 0.6975 <0.0001A
rs1763598 I2–483 Intronic A G  0.8775 0.8424 0.0662
rs1739841 I2–473 Intronic T C  0.4802 0.6451 <0.0001A
rs1763599 I2–348 Intronic G A  0.6009 0.7442 <0.0001A
rs61783988 I2–343 Intronic T C  0.0779 0.0305 0.0002A
rs76176 I2–165 Intronic T C  0.5307 0.6803 <0.0001A
rs761759 I2–96 Intronic T A  0.5519 0.7080 <0.0001A
rs173984 +351 Coding S C T T117T 0.4735 0.3096 <0.0001A
PLN
rs73526175 I1–206 Intronic G T  0.0030 0.0710 <0.0001A
 I1–105 Intronic A G  0.0013 0.0043 0.3029
rs12198461 +556 3′UTR T G  0.5238 0.4181 <0.0001A
 +1,575 3′FR G A  0.0209 0.0624 <0.0001A
rs9489441 +1,736 3′FR G C  0.0029 0.0781 <0.0001A
rs151429 +1,737 3′FR C T  0.7017 0.7003 0.9529
Allele frequencies from Illumina resequencing of 7 DNA pools from 625 nonaffected Caucasians and 3 
DNA pools from 237 nonaffected African Americans. For SNPs in HapMap, the rs number from dbSNP 
(19) is shown. Position of exonic SNPs is relative to +1 position of the translation initiation codon, and of 
SNPs within introns is relative to the nearest exon. I1, first intron; I2, second intron; S, synonymous; NS, 
nonsynonymous; UTR, untranslated region; FR, flanking region. Values in the codon column show the 
amino acid. Only those SNPs found to occur in both Caucasian and African Americans are shown; Supple-
mental Table 1 shows all 110 SNPs. AP < 0.0005, the threshold for this study (α = 0.05, n = 110).
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information to a case-control SNP association analysis of sporad-
ic ischemic and nonischemic cardiomyopathy. To our knowledge, 
this is the first large-scale application of next-generation sequenc-
ing technologies to study a disease using pooled DNA samples; 
therefore, we were careful to validate the approach and to repli-
cate our findings, both within the primary study cohort and in an 
independent systolic heart failure cohort. We found that Illumi-
na resequencing of DNA pools containing about 100 individual 
DNAs was rapid, accurate, and highly sensitive for identifying 
common and rare or private SNPs and had striking advantages 
in time and cost efficiencies over individual resequencing. Our 
results identified, and verified by independent replication, a clus-
ter of SNPs within a haplotype block of HSPB7 that were associat-
ed with development of systolic heart failure. Interestingly, none 
of the associated SNPs altered amino acid coding of HSPB7 pro-
tein, nor were nonsynonymous SNPs independently associated 
with heart failure, even those predicted to be functionally delete-
rious. The present studies demonstrate the power and potential 
broad applicability of pooled resequencing for comparative SNP 
association analysis of target subgenomes in large populations 
and describe what we believe to be a previously unsuspected asso-
ciation between HSPB7 and sporadic heart failure.
Applicability of pooled resequencing with next-generation platforms. 
Much of the low-hanging fruit from human genetic studies has 
been picked over. Thousands of disease-causing gene mutations 
have been identified, and millions of relatively common gene 
polymorphisms have been cataloged, yet the impact of these find-
ings has primarily been on rare inherited diseases that are almost 
entirely genetic in cause. The next step is to elucidate the more 
modest genetic effects attributable to simultaneous influences of 
multiple noncausal gene variants on common diseases that are not 
primarily genetic (8). This requires sequencing many thousands of 
individual human genomes at a resolution of individual nucleo-
tides, which we accomplished via a recently developed and vali-
dated pooled sequencing strategy (11). Our procedure accurately 
detected variant alleles across a wide range of frequencies in Cau-
casian and African American normal controls and in heart failure 
subjects. Results for ADRA1A exon 2, in which there were SNPs 
covering the entire range of allele frequencies (but no difference in 
allele frequencies between heart failure cases and controls), were 
confirmed by individual Sanger sequencing of the entire study 
cohort. Importantly, this pooled sequencing protocol generated 
these data for a much smaller investment of time and resources 
compared with conventional methods that rely upon serial geno-
Figure 3
Comparative analysis of SNP allele frequencies in 
population subgroups. (A) Comparison of target gene 
SNP allele frequencies in African Americans versus 
Caucasians. Vertical axis is African American allele 
frequency/Caucasian allele frequency, plotted on a 
log10 scale. Horizontal axis shows target gene with 
SNPs positioned accordingly, as in Figure 1. Red sym-
bols denote novel SNPs. The shaded area indicates 
less than 2-fold difference in relative allele frequency. 
Symbols at the extreme top and bottom represent 
alleles seen exclusively in African Americans and 
Caucasians, respectively (see Table 2). (B) Linkage 
analysis of HSPB7 SNPs in Caucasians and associa-
tion with systolic heart failure. HSPB7 SNP positions 
are shown within the gene (schematic as in Figure 1; 
boxes denote SNPs present in HapMap). Allele fre-
quencies were compared across pools of 100 individu-
als. Red shading in the linkage plot denotes r2 ≥ 0.90; 
blue shading denotes r2 > 0.70; no shading denotes 
r2 < 0.70. Numbers within plot show r2 values (×100). 
Asterisks denote SNPs significantly associated with 
Caucasian heart failure (P < 0.0014; see Table 4).
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typing of each individual in each cohort. Extrapolating the time 
and cost of individual capillary resequencing versus Illumina rese-
quencing of pools of about 100 individual DNAs (referred to here-
in as the 29-pool study), accurate allele frequencies and detection 
of very rare and private SNPs was achieved in the current instance 
for one-sixteenth the cost and about one-thirtieth the time and 
effort. If the experimental design requires only quantification of 
alleles with frequencies greater than 0.01 (i.e., prevalence more 
than 1%), then there appears to be no disadvantage to using a larg-
er, about 250-individual DNA pooling strategy at an additional 
doubling of the cost savings. These cost and time efficiencies are 
expected to further improve with double-end reading and further 
technological advances, and the protocols can be applied to any 
genes in virtually any population of interest. For example, pooled 
resequencing of large, existing cardiovascular study populations 
could rapidly identify and quantify biologically relevant SNPs in 
cardiac contractile protein genes, ion pump and channel genes, or 
transcription factor genes (30–32).
SNP associations with systolic heart failure. The current study focused 
on 4 signaling genes, selected for their potential importance in 
cardiac disease and (in these initial pooled resequencing studies) 
for their uncomplicated genetic structure. Polymorphisms of the 
α1-adrenergic receptor, encoded by ADRA1A, have been linked with 
hypertensive disease in some, but not all, populations (33–35). It 
Table 4
Comparative allele frequencies of common HSPB7 SNPs in Caucasian heart failure
dbSNP	 Position	 Type	 Major	 Minor	 Codon	 Primary	 Primary	 Fisher	 Adjusted	 Secondary	 Secondary	 Fisher	 Adjusted	
	 	 	 allele	 allele	 	 controls	 cases	 exact	 c2	 controls	 cases	 exact	 c2
rs3738640 –8 5′UTR G A  0.106 0.102 0.6847 0.7246 
rs945416 +57 Coding S C T S19S 0.538 0.606 0.0001A 0.0001A 0.510 0.582 0.0025B 0.0001B
rs732286 +99 Coding S T C A33A 0.517 0.594 <0.0001A <0.0001A 0.489 0.575 0.0003B <0.0001B
rs3883891 I1+177 Intronic A G  0.373 0.424 0.0032 0.0040 
rs1763596 I1-133 Intronic G A  0.538 0.619 <0.0001A <0.0001A 0.506 0.576 0.003B 0.0001B
rs1739845 I1-113 Intronic G T  0.050 0.052 0.8732 0.8168 
rs3738643 I2+245 Intronic C G  0.112 0.098 0.2454 0.2156 
rs1739844 I2+247 Intronic A G  0.511 0.589 <0.0001A <0.0001A 0.480 0.571 0.0001B <0.0001B
rs1763597 I2+272 Intronic G A  0.528 0.618 <0.0001A <0.0001A 0.515 0.575 0.0109B 0.0008B
rs1739843 I2+315 Intronic A G  0.543 0.624 <0.0001A <0.0001A 0.495 0.585 0.0001B <0.0001B
rs12758813 I2+490 Intronic C T  0.417 0.450 0.0696 0.0654 
rs1739842 I2-594 Intronic A C  0.524 0.615 <0.0001A <0.0001A 0.480 0.568 0.0002B <0.0001B
rs1763598 I2-483 Intronic A G  0.878 0.898 0.0796 0.0836 
rs1739841 I2-473 Intronic T C  0.480 0.578 <0.0001A <0.0001A 0.405 0.506 <0.0001B <0.0001B
rs1763599 I2-348 Intronic G A  0.601 0.666 0.0001A 0.0002A 0.554 0.633 0.0006B <0.0001B
rs61783988 I2-343 Intronic T C  0.078 0.075 0.7903 0.7652 
rs761760 I2-165 Intronic T C  0.531 0.598 0.0001A 0.0002A 0.484 0.570 0.0003B <0.0001B
rs761759 I2-96 Intronic T A  0.552 0.632 <0.0001A <0.0001A 0.456 0.581 <0.0001B <0.0001B
rs1739840 +351 Coding S C T T117T 0.473 0.399 <0.0001A <0.0001A 0.561 0.443 <0.0001B <0.0001B
Allele frequencies of common SNPs in HSPB7 from Illumina resequencing of 7 DNA pools from 625 nonaffected primary controls, 12 DNA pools from 
1,117 primary cases, 4 DNA pools from 311 nonaffected secondary controls, and 10 DNA pools from 825 secondary cases. For SNPs in HapMap, the rs 
number from dbSNP (19) is shown. Position is from the translation initiation codon. I1, first intron; I2, second intron; S, synonymous; UTR, untranslated 
region. Values in the codon column show the amino acid. Comparative allele frequencies of all 37 common target gene SNPs are given in Supplemental 
Table 2. Statistical comparisons used Fisher exact and adjusted c2 tests as described in Methods. AP < 0.0014, the threshold for the primary study  
(α = 0.05, 2-tailed test; n = 37). BP < 0.0212, the threshold for the replication study (α = 0.05, 2-tailed test; effective number of independent SNPs, 2.36).
Table 3
Clinical characteristics of study cohorts
	 Primary	controls	 Primary	CHF	 Secondary	controls	 Secondary	CHF
Variable	 Cauc	 AA	 Cauc	 AA	 Cauc	 Cauc
N 625 236 1,117 628 311 859
Age (yr) 48.74 ± 12.0 54.0 ± 13.3 57.1 ± 13.2 54.0 ± 13.3 58.0 ± 10.9 58.5 ± 13.1
Height (in.) 67.6 ± 4.2 66.4 ± 5.01 67.7 ± 4.1 67.0 ± 4.2 67.7 ± 4.0 68.2 ± 4.0
Weight (lb) 182.7 ± 45.1 194.3 ± 46.5 193.0 ± 50.0 197.2 ± 55.9 186.4 ± 43.7 189.2 ± 44.5
Ejection fraction (%) – – 28.7 ± 13.2 26.9 ± 11.5 66.0 ± 6.3 31.8 ± 16.2
CHF etiology (n)
 Ischemic – – 689 (60%) 295 (47%) – 286 (50%)
 Nonischemic – – 427 (40%) 332 (53%) – 285 (50%)
 Female 375 (60%) 184 (77%) 359 (32%) 285 (46%) 138 (44%) 158 (28%)
 Hypertension 16 (3%) 1 (0%) 794 (69%) 568 (91%) 144 (47%) 252 (44%)
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is striking that our studies detected 14 nonsynonymous polymor-
phisms of this receptor, 8 of which were rare and not previously 
reported in dbSNP (Table 2 and ref. 19). To our knowledge, there 
are no published reports of associations between ADRA1A vari-
ants and development of heart failure, and no significant associa-
tions were detected in our studies. Likewise, β2-adrenergic recep-
tors, encoded by ADRB2, mediate the cardiac inotropic response to 
catecholmines and are the targets of β-blocking drugs. This gene 
is highly polymorphic (10 nonsynonymous SNPs in our study, 
5 rare and previously unreported), but does not appear to contrib-
ute to heart failure risk in our present study or in previous stud-
ies (36). Phospholamban, encoded by PLN, is a critical regulator 
of cardiomyocyte calcium cycling that transmits inputs from the 
β-adrenergic receptor system to the major sarcoplasmic reticulum 
calcium reuptake pump, SERCA2 (37). In dramatic contrast to 
the results for the 2 adrenergic receptors, not a single nonsynony-
mous polymorphism for PLN was detected in the more than 2,600 
individuals of our cohort. This remarkable degree of amino acid 
sequence conservation was consistent with the severe pathologi-
cal consequences previously described with loss-of-function PLN 
mutants. Substitution of cysteine for arginine at amino acid 9 (16), 
introduction of a premature stop codon at amino acid 39 (38), and 
deletion of arginine 14 (17, 39) each cause a familial cardiomyopa-
thy with potentially lethal repercussions.
HSPB7, also referred to as cvHSP (18), has not previously been 
systematically examined for genetic variation. However, because 
an array-based analysis of approximately 2,000 candidate car-
diovascular genes found a significant association between the 
intronic HSPB7 SNP rs1739843 and heart failure (T.P. Cappola 
and G.W. Dorn II, unpublished observations), we included it in 
our resequencing study. We detected 39 HSPB7 SNPs, of which 18 
were either rare or observed exclusively in the African American 
subgroup (Table 2); to our knowledge, all were previously unre-
ported. Of the HSPB7 SNPs, 12 were associated with systolic heart 
failure, and these associations were independently validated in a 
second heart failure population. HSPs are upregulated in response 
to stress and exhibit a variety of cytoprotective effects through 
their function as molecular chaperones (40). A nonsynonymous 
polymorphism of HSP20 that lacks its characteristic cytoprotec-
tive effects has been described previously (41). However, none of 
the associated HSPB7 SNPs changed an amino acid in HSPB7. 
To determine whether a functionally significant noncoding SNP 
might account for the association with heart failure, we examined 
the most recent list from the miRBase database of all the genomic 
locations of known human miR precursors; none were within 
10 Mb of HSPB7 (our unpublished observations). We also subject-
ed the area we sequenced to TargetScan analysis, which showed 
only 1 SNP (that occurred only in African Americans and was not 
significantly associated in the case-control analysis) in a poorly 
conserved binding site for hsa-miR-1207-5p (our unpublished 
observations). Finally, we looked at proximity of the HSPB7 SNPs 
to splice acceptor and splice donor sites; none were closer than 50 
nucleotides (our unpublished observations). However, because the 
associated HSPB7 SNPs were in linkage disequilibrium within a 
haplotype block that extends beyond the HSPB7 gene, we speculate 
that the causative genetic event may be in another gene or in the 
intergenic region. Further examination of this locus by resequenc-
ing may help establish a mechanism for the genetic findings.
Nonsynonymous signaling gene SNPs. A major advantage of exomic 
sequencing is the potential to identify rare gene variants typically 
missed by linkage analysis with microsatellite markers or marker 
SNPs. Any specific rare SNP, by definition, affects a small propor-
tion of individuals and therefore tends to be discounted. As a class, 
however, rare SNPs can be collectively common, as evidenced by 
our observation that, of the 129 SNPs identified in this study, 74 
(57.4%) had a prevalence of less than 1%. Because pathological 
effects of variant gene products produce selective pressure against 
sequence variation, a high proportion of rare nonsynonymous 
SNPs can be detrimental (27) and are therefore particularly impor-
tant to catalog. Here, we identified 23 novel nonsynonymous SNPs 
(Supplemental Table 6) that — although they were not associated 
with increased risk for development of systolic heart failure in this 
study — may merit closer examination as potential modifiers of 
sporadic cardiomyopathy or of other diseases. To that end, using 
bioinformatics to classify nonsynonymous SNPs by their prob-
ability for pathological impact provides a mechanism for initial 
titration of SNPs for further mechanistic evaluation.
Limitations. Pooled sequencing, as used herein, can rapidly gen-
erate accurate SNP frequency data for a large study cohort, but 
does not provide genetic information at the individual level. Con-
sequently, the data are not readily useful for assessment of relative 
risk. However, an estimate of carrier prevalence can be generated if 
one assumes that the SNPs conform to the predictions of Hardy-
Weinberg equilibrium (42). With this caveat, the HSPB7 SNPs iden-
tified herein increase the odds of developing systolic heart failure 
by an average of 1.55 ± 0.02–fold (Supplemental Table 7).
Pooled exomic sequencing is optimized for large-scale compari-
sons of allele frequencies between, or within, populations, as with 
case-control studies of disease or studies comparing populations 
of genetic/geographic ancestry. We have found that the technique 
and data analysis pipeline can be modified to incorporate indi-
vidual PCR amplification and DNA barcoding prior to DNA pool-
ing to obtain personal sequence, while taking advantage of the 
high throughput and efficiencies of pooled resequencing on the 
Illumina Genome Analyzer II (G.W. Dorn II and S.J. Matkovich, 
unpublished observations).
The nature of population genetics research, either using high-den-
sity genome-wide SNP microarrays to identify loci linked with dis-
ease or using targeted subgenome resequencing to identify specific 
SNPs associated with disease, is that the significant genetic events 
do not necessarily define the causal genetic events. Our study pro-
vides an example of this, in that multiple replicated and validated 
HSPB7 SNPs associated with development of systolic heart failure 
in Caucasians do not, as far as we can determine using available 
bioinformatics resources, affect gene or protein function. Thus, the 
mechanism for these findings is unclear and will require both addi-
tional resequencing and case-control studies to identify linked SNPs 
that may be causal and wet laboratory work to define the functional 
impact of those SNPs at the cellular and organism levels.
Our SNP discovery efforts were performed in Caucasians and 
African Americans, and the heart failure case-control study was 
limited to systolic heart failure in Caucasians. The impact of our 
findings was not addressed in groups with different geographic 
ancestry, such as Hispanic and Asian populations, although the 
approach described herein would be ideal to do so.
In summary, we have demonstrated the accuracy and utility 
of pooled sequencing to identify previously unknown rare gene 
variants, to compare polymorphism expression between different 
ancestral populations, and to identify novel associations between 
HSPB7 polymorphisms and sporadic systolic heart failure in Cau-
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casians. This approach will be generally useful to identify disease-
associated SNPS in gene-ontology clusters informed by array-
based genome-wide association studies and by existing databases 
of gene expression or as suggested by biological rationale.
Methods
Study subjects. Human study protocols were approved by the Institutional 
Review Boards of the University of Cincinnati or the University of Penn-
sylvania. All subjects provided written informed consent. Subjects with 
systolic heart failure were recruited, from patients presenting to the heart 
failure referral program at the University of Cincinnati or the University 
of Pennsylvania, into 1 of 2 longitudinal studies of heart failure genom-
ics funded by the National Heart, Lung, and Blood Institute (NHLBI; P50 
HL77101 and R01 HL88577). Enrollment criteria were age 18–80 years, 
clinical diagnosis of systolic heart failure, and documented abnormal left 
ventricular function (ejection fraction <40%) by noninvasive cardiac imag-
ing. African American inclusion at greater than 25% of the total cohort was 
part of the NHLBI-approved study design. Nonaffected controls, in whom 
clinical heart failure was not present, echocardiographic left ventricular 
function was normal (ejection fraction >50%, no wall motion abnormali-
ties), and there was no evidence for clinically significant coronary artery 
disease, were from the greater Cincinnati and Philadelphia metropolitan 
areas. DNA from a total of 2,606 individuals was studied in the primary 
cohort: 1,117 Caucasian heart failure subjects, 625 Caucasian nonaffected 
controls, 628 African American heart failure subjects, and 236 African 
American nonaffected controls. The secondary replication cohort con-
sisted of 859 Caucasian systolic heart failure cases and 311 Caucasian 
nonaffected controls. Detailed clinical features of these heart failure study 
populations were recently reported (20).
DNA preparation, pooling, and amplification. Genomic DNA was isolated and 
extracted using the Gentra Puregene genomic DNA purification kit (Qiagen) 
and individually quantified by PicoGreen (Invitrogen) fluorescence in a 96-
well format. For our initial validation experiments, 25 ng DNA from each 
individual was combined into pools, as shown in Supplemental Figure 1. 
DNA segments containing the regions of interest were individually PCR 
amplified using specific primers (Supplemental Table 8) and PfuUltra high-
fidelity polymerase (Stratagene) from each of the pools, using an average of 
30 diploid genomes (approximately 0.2 ng DNA) per individual as input into 
a total of 7 PCR reactions that included 9,389 bases from 4 genes: ADRA1A, 
ADRB2, HSPB7, and PLN (Supplemental Table 8). Preparation of the PCR 
products for sequencing on the Illumina Genome Analyzer I or II was as 
described previously (11). Briefly, amplicons were purified from primers and 
residual nucleotides by Qiaquick column separation (Qiagen), combined 
into mixtures containing an equivalent number (1 × 1011) of molecules of 
each amplicon, and concatenated overnight at 22°C with T4 DNA ligase and 
T4 polynucleotide kinase (New England Biolabs) in the presence of 15% (w/v) 
polyethylene glycol, MW8000 (Sigma-Aldrich). pBluescript control DNA 
amplicons were included in ligations to monitor base calling accuracy. After 
10-fold dilution in buffer PB (Qiagen), random fragmentation by sonica-
tion (Diagenode Bioruptor XL), and purification on Qiaquick columns (Qia-
gen), the DNA was end repaired, ligated to Illumina sequencing adapters, 
and prepared for analysis per Illumina protocol. Individual resequencing of 
ADRA1A exon 2 in the entire primary cohort was performed by dye termina-
tor sequencing using an ABI 3730xl capillary sequencer (17, 43).
Sequence analysis. As previously demonstrated, the likelihood of sequenc-
ing errors across the 36-bp Illumina read across bases 1–12 averages 
0.00065, rises dramatically after base 12, and can vary significantly from 
run to run (11). To model these errors, a 1,655-bp amplicon from the pBlue-
script backbone was incorporated into the ligation of PCR products and 
used to define an error model for each sequencing run. Sequencing output 
was aligned against an annotated reference gene sequence, consisting of 
only the regions amplified, downloaded from the UCSC Genome Browser 
(44). Illumina reads were aligned against the reference by allowing 2 mis-
matches or fewer for each read. Any read with more than 2 mismatches or 
that aligned to multiple locations in the reference sequence was eliminated 
from SNP calling. SNPSeeker used only the first 12 highly accurate bases 
of each read along with a second-order dependency model to identify SNPs 
in all regions of interest. Therefore, whereas all 36 bases of each read were 
used for alignment to reference, only bases 3–12 of each 36-base read were 
effectively used for SNP identification. Because a single allele occurs at a 
frequency of 0.002 in a pool of 250 individuals (and at a frequency of 0.005 
in a pool of 100 individuals), a singleton will be present at a frequency at 
least about 3-fold more prevalent than error in a given sequencing lane. We 
defined common SNPs as those occurring at a frequency of at least 0.01 in 
subjects of similar geographic ancestry, whereas the lower limit of detec-
tion for rare SNPs was a frequency of 0.0003 for all Caucasians (1 allele in 
the entire cohort of 1,742 individuals) and a frequency of 0.0006 for all 
African Americans (1 allele in 864 individuals).
For each gene, all available sequences were downloaded from dbSNP (19) 
and mapped onto an annotated reference gene sequence downloaded from 
the UCSC Genome Browser (44). Names were assigned according to the 
nomenclature suggested by the Human Genome Variation Society (45), in 
which the +1 position denotes the translation initiation codon, and num-
bering of SNPs within introns depends on proximity to the nearest exon.
Comparative genomic analysis. SIFT (28) and PolyPhen (29) analyses were 
conducted with the default parameter settings.
Statistics. Allele frequencies for all SNPs were compared with a Pearson’s 
correlation coefficient. To assess differences in clinical variables, 2-tailed 
Student’s t test was used. Fisher exact test or adjusted c2 test (see below) 
were used to compare allele frequencies. The P level threshold for signifi-
cance in the primary heart failure case-control analysis was P < 0.0014, 
using a Bonferroni correction for multiple testing (n = 37 common SNPs 
at α = 0.05). Prior to the replication study, linkage between the associated 
HSPB7 SNPs was assessed. Allele frequency correlations across pools and 
eigenvalues were calculated using the R package per Gao et al. (46), and 
these were used to derive the effective number of independent SNPs (Meff) 
by the equation Meff = 1 + [(M – 1) (1 – [Var(λobs)]/M)], in which M is the 
total number of variables in the matrix and Var(λobs) is the variance of the 
observed eigenvalues (47). The calculated Meff of 2.37 was then used in a 
Bonferroni correction to derive a threshold P value of P < 0.0212 (α = 0.05). 
To account for variance due to DNA pooling, an estimate of pooling error 
was calculated according to Visscher and Le Hellard (48). The resulting 
error factor of 0.014 was then used to adjust the c2 test statistic.
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